A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Author(s): Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA
Affiliation(s): Neurosciences Department, Monash Medical Centre, Melbourne, Australia.
Publication date & source: 2011-07, Mov Disord., 26(8):1552-5. Epub 2011 Apr 29.
BACKGROUND: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. METHODS: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period. RESULTS: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05). CONCLUSIONS: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. (c) 2011 Movement Disorder Society. Copyright (c) 2011 Movement Disorder Society.